Combining two enzymes to break down fish processing waste produced peptides with over 60% ACE inhibition (antihypertensive potential) and strong antioxidant activity.
>60% ACE inhibitionFish waste-derived peptides inhibited the blood pressure-regulating enzyme ACE by over 60% at 5 mg/mL concentration
What the researchers found
Single-stage combined enzymatic hydrolysis (Alcalase + Protana) achieved 80% protein yield and 34-49% degree of hydrolysis, producing low-molecular-weight peptides. Hydrolysates showed ABTS antioxidant activity with EC50 below 5 mg/mL and over 60% ACE inhibition at 5 mg/mL. Gilthead seabream co-products yielded the most promising bioactive peptides.
Why it matters
Millions of tons of fish processing waste are discarded annually. Converting this waste into bioactive peptides with health-promoting properties — particularly blood pressure management — creates value from what was previously a financial loss while addressing sustainability challenges.
The numbers in context
3 fish species' co-products tested with 4 enzymatic systems: Alcalase and others. Products included heads/bones, carcasses, and trimmings.
How the study worked
Laboratory study testing four enzymatic hydrolysis systems (endopeptidase alone, exopeptidase alone, sequential two-stage, and combined single-stage) on co-products from three fish species. Hydrolysates evaluated for protein yield, degree of hydrolysis, molecular weight distribution, antioxidant activity (ABTS assay), ACE inhibition, and antidiabetic/anti-Alzheimer properties.
Who was studied
Laboratory analysis of fish processing co-products
What this study cannot tell us
In vitro study only — ACE inhibition in a test tube doesn't guarantee blood pressure reduction in humans. Bioavailability and stability of these peptides through digestion not tested. No dose-response or toxicity studies. Antidiabetic and anti-Alzheimer activities were low and likely not clinically meaningful.
How to read the evidence
Rated preliminary: in vitro study demonstrating bioactivity in test tubes only. No animal or human data on actual blood pressure or health outcomes.
When this study was published
Published in 2024. Represents current work in sustainable marine bioactive peptide production.
The bigger picture
This work fits into the growing field of sustainable bioactive peptide production. As demand increases for natural alternatives to pharmaceutical blood pressure and antioxidant treatments, marine-derived peptides from waste streams offer both environmental and health benefits.
Questions still open
- Do these fish-derived ACE-inhibitory peptides survive digestion and remain active in the human body?
- Could these peptides be formulated into functional foods or supplements with measurable blood pressure effects?
- How do the bioactivities compare to established marine peptide products already on the market?
Common questions
Can fish waste be turned into health supplements?
Do fish peptides really lower blood pressure?
Read the original research
Enzymatic Hydrolysis Systems Enhance the Efficiency and Biological Properties of Hydrolysates from Frozen Fish Processing Co-Products.
Marine drugs, 23(1)
Citation
Sapatinha, Maria; Camacho, Carolina; Pais-Costa, Antónia Juliana; Fernando, Ana Luísa; Marques, António; Pires, Carla. (2024). Enzymatic Hydrolysis Systems Enhance the Efficiency and Biological Properties of Hydrolysates from Frozen Fish Processing Co-Products.. Marine drugs, 23(1). https://doi.org/10.3390/md23010014